Clear Street raised the firm’s price target on Delcath Systems (DCTH) to $28 from $27 and keeps a Buy rating on the shares. The stock is trading lower on the company’s “soft” preliminary Q3 results and 2025 revenue guidance, the analyst tells investors in a research note. However, the firm attributes the results to pricing dynamics and new patient starts, which it feels are “likely a blip.” The CHOPIN trial results will lead to increased penetration of Hpezato into the metastatic uveal melanoma population, contends Clear Street. The firm sees today’s selloff as a buying opportunity. The stock is down 5% to $11.38 in midday trading.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems price target lowered to $30 from $31 at H.C. Wainwright
- Delcath Systems: Promising Growth Potential Amidst Challenges with Strong Buy Rating
- Delcath Systems Reports Positive CHOPIN Trial Results
- Delcath Systems announces investigator-initiated CHOPIN Phase 2 presentation
- Delcath Systems management to meet with Craig-Hallum